A trial of long-acting sulphonamide R.O. 4-4393 (fanasil) in treatment of cases of lepromatous leprosy with repeated E.N.L.
A trial of long-acting Sulphonamide RO.4-4393 (Fanasil) in the treatment of Lepromatous Leprosy patients with repeated E.N.L. is reported in this paper. There were 9 patients treated with Fanasil in this trial for a period of 2 years. The results of the trial have shown that the treatment with Fanasil helps to prevent the occurrence of E.N.L. under treatment with D.D.S. In addition, even after the completion of treatment with Fanasil, these patients seem to be stabilised and are able to tolerate D.D.S. But, the clinical and Bacteriological progress under Fanasil therapy is not satisfactory.
D003622:Dapsone / Q000009:adverse effects / Q000627:therapeutic use; D004893:Erythema Nodosum / Q000209:etiology; D006801:Humans; D007918:Leprosy / Q000150:complications / Q000188:drug therapy*; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use*
D013449:Sulfonamides; D003622:Dapsone